BR112023025616A2 - Codificação de ácido nucleico para proteína de fusão klk2-gpi, células recombinantes e usos das mesmas - Google Patents

Codificação de ácido nucleico para proteína de fusão klk2-gpi, células recombinantes e usos das mesmas

Info

Publication number
BR112023025616A2
BR112023025616A2 BR112023025616A BR112023025616A BR112023025616A2 BR 112023025616 A2 BR112023025616 A2 BR 112023025616A2 BR 112023025616 A BR112023025616 A BR 112023025616A BR 112023025616 A BR112023025616 A BR 112023025616A BR 112023025616 A2 BR112023025616 A2 BR 112023025616A2
Authority
BR
Brazil
Prior art keywords
klk2
fusion protein
nucleic acid
gpi
recombinant cells
Prior art date
Application number
BR112023025616A
Other languages
English (en)
Portuguese (pt)
Inventor
L Emanuel Stuart
J Rutkoski Thomas
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112023025616A2 publication Critical patent/BR112023025616A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21035—Tissue kallikrein (3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • C07K2319/912—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation containing a GPI (phosphatidyl-inositol glycane) anchor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112023025616A 2021-06-10 2022-06-08 Codificação de ácido nucleico para proteína de fusão klk2-gpi, células recombinantes e usos das mesmas BR112023025616A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163209019P 2021-06-10 2021-06-10
PCT/IB2022/055355 WO2022259190A1 (en) 2021-06-10 2022-06-08 Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof

Publications (1)

Publication Number Publication Date
BR112023025616A2 true BR112023025616A2 (pt) 2024-02-27

Family

ID=82358484

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023025616A BR112023025616A2 (pt) 2021-06-10 2022-06-08 Codificação de ácido nucleico para proteína de fusão klk2-gpi, células recombinantes e usos das mesmas

Country Status (11)

Country Link
US (1) US20220403397A1 (cg-RX-API-DMAC7.html)
EP (1) EP4352217A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520790A (cg-RX-API-DMAC7.html)
KR (1) KR20240021211A (cg-RX-API-DMAC7.html)
CN (1) CN117480253A (cg-RX-API-DMAC7.html)
AU (1) AU2022291273A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023025616A2 (cg-RX-API-DMAC7.html)
CA (1) CA3222756A1 (cg-RX-API-DMAC7.html)
IL (1) IL309179A (cg-RX-API-DMAC7.html)
MX (1) MX2023014793A (cg-RX-API-DMAC7.html)
WO (1) WO2022259190A1 (cg-RX-API-DMAC7.html)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5602299A (en) 1992-09-23 1997-02-11 Mount Sinai School Of Medicine Of The City University Of New York Transgenic animal models for neurodegenerative disease
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
US5516639A (en) * 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US6113917A (en) * 1995-04-25 2000-09-05 Rmf Dictagene S.A. Modified polypeptides for enhanced immunogenicity
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
WO2004098529A2 (en) * 2003-04-30 2004-11-18 Emory University Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
JP4549666B2 (ja) * 2003-12-12 2010-09-22 タカラバイオ株式会社 抗体の製造方法
ATE440949T1 (de) * 2004-01-30 2009-09-15 Maxygen Holdings Ltd Gesteuertes überlesen von stopcodons
KR20070084330A (ko) * 2004-10-18 2007-08-24 지모제넥틱스, 인코포레이티드 가용성 zcytor21, 항-zcytor21 항체 및 결합파트너 및 염증에서의 사용방법
EP2315846A4 (en) * 2008-08-05 2011-11-30 Univ Rochester PSA AND KLK2 AS THERAPEUTIC TARGET MOLECULES AND PSA AND KLK2-INHIBITABLE MOLECULES
JP6092782B2 (ja) * 2010-11-16 2017-03-08 エクセリミューン, インコーポレイテッド 組換えタンパク質の製造方法
EP3218477A4 (en) * 2014-11-10 2018-07-18 The Board of Trustees of The Leland Stanford Junior University Compositions and methods for expressing polypeptides on the surface of cells
TW202118792A (zh) * 2019-07-26 2021-05-16 美商健生生物科技公司 抗hk2嵌合抗原受體(car)

Also Published As

Publication number Publication date
EP4352217A1 (en) 2024-04-17
JP2024520790A (ja) 2024-05-24
WO2022259190A1 (en) 2022-12-15
IL309179A (en) 2024-02-01
US20220403397A1 (en) 2022-12-22
MX2023014793A (es) 2024-03-25
AU2022291273A1 (en) 2024-01-25
CA3222756A1 (en) 2022-12-15
CN117480253A (zh) 2024-01-30
KR20240021211A (ko) 2024-02-16

Similar Documents

Publication Publication Date Title
BR112023005674A2 (pt) Construtos anti-cd93 e usos dos mesmos
BR112022015628A2 (pt) Vacina de sars-cov-2
BR112022021459A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
ES2662402T3 (es) Neurotoxinas recombinantes de Clostridium botulinum
WO2021198706A3 (en) Coronavirus vaccines
BR112021017486A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112022024629A2 (pt) Construtos anti-cd93 e seus usos
AR038568A1 (es) Anticuerpos anti-a beta y su uso
NO20020861L (no) Nye B7-4-molekyler og anvendelser derav
BR112023004040A2 (pt) Mutante de il-2 e sua aplicação
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
MX2019000743A (es) Variantes de serinproteasa y polinucleotidos que las codifican.
BR112021017491A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112021017479A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112022010095A2 (pt) Proteínas gpcr de opsina quimérica
BR112021017467A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112021017404A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112023002578A2 (pt) Variantes de fitase e polinucleotídeos codificando as mesmas
BR112023003468A2 (pt) Variantes de uma xiloglucanase da família 44
MX2022013416A (es) Polipeptidos de fusion para la produccion de peptidos objetivo.
NO20062948L (no) Promotere for ekspresjon i modifisert vaccinia-virus Ankara
Takemori et al. Top-down/bottom-up mass spectrometry workflow using dissolvable polyacrylamide gels
AR129131A2 (es) POLIPÉPTIDOS DE INTERLEUCINA-2 MUTANTE DEPENDIENTES DEL pH
ZA202310639B (en) Interleukin 15 variants

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.1 NA RPI NO 2841 DE 17/06/2025 POR TER SIDO INDEVIDA.